Premarket Approval Applications (PMAs), Product Development Protocols (PDPs), and Humanitarian Device Exemptions
|
|
- Dorothy Lamb
- 7 years ago
- Views:
Transcription
1 FDLI s Introduction to Medical Device Law and Regulation: Understanding How FDA Regulates the Medical Device Industry October 28-29, 2002 The Westin Grand Hotel Washington, D.C. Premarket Approval Applications (PMAs), Product Development Protocols (PDPs), and Humanitarian Device Exemptions presented by Suzan Onel, Partner Kirkpatrick & Lockhart, LLP 1800 Massachusetts Ave., N.W. Washington, D.C Phone: Fax: sonel@kl.com DC v
2 PREMARKET APPROVAL APPLICATIONS (PMAs), PRODUCT DEVELOPMENT PROTOCOLS (PDPs), AND HUMANITARIAN DEVICE EXEMPTIONS Suzan Onel, Esq. I. PMA REVIEW (FDCA 515 (21 U.S.C. 360(e)); 21 C.F.R. Part 814) A. Overview. 1. Standard: Reasonable Assurance Of Safety and Effectiveness. 2. Filing Date Is Date FDA Receives Complete PMA. 3. Clock Is 180-Day Review Time. 4. Substantial Changes Will Restart The Clock. 5. Review By FDA Personnel And Possibly Referred To FDA Advisory Committee. 6. FDA Notifies Applicant Of Approval By Letter. 7. Notice Announcing The Decision And Availability Of Summary Of Safety And Effectiveness Data Used To Be Published In Federal Register, Now On Internet. B. Early Collaboration Meetings. 1. Determination Meeting Type Of Scientific Evidence That Will Be Required. FDCA 513(a)(3)(D). 2. Agreement Meeting Pre-IDE Meeting To Agree On Investigational Plan. FDCA 520(g)(7). 3. Binding On The Agency Unless Contrary To Public Health. 4. Early Collaboration Meetings Under the FDA Modernization Act (FDAMA), Guidance for Industry and CDRH Staff (Feb. 19, 1998) [Exhibit 1] C. PMA Application Should Contain (21 C.F.R ): See PMA Manual at and PMA Elements Used [Exhibit 2] 1. Name And Address Of Applicant. 2
3 2. Comprehensive Summary. 3. Complete Description Of The Device Including Photographs And Drawings. 4. Full Reports Of Investigations On Safety And Effectiveness. 5. Components. 6. Methods And Controls Used For Manufacturing Or Processing. 7. Reference To Any Performance Standard Under 21 U.S.C Bibliography Of All Publications. 9. Summary Of Unpublished Information. 10. Statement That Nonclinical Studies Meet FDA Requirements (21 C.F.R. 58). 11. Summary Of Clinical And Nonclinical Investigation. 12. Investigator Financial Disclosure Or Certification 13. Sample (When Reasonable). 14. Labeling, Literature And Installation Instructions. 15. An Environmental Assessment. 16. If Only One Investigator Has Participated, A Justification That A Single Investigator Was Sufficient To Demonstrate Safety And Effectiveness Of Device. D. Filing The PMA Application. 1. Send To: Document Mail Center Food and Drug Administration HFZ Corporate Blvd. Rockville, MD (301) FDA Will Acknowledge Receipt And Provide Unique Application Number. 3. Only Authorized Person Submitting Application Can Obtain Information. 3
4 4. FDA, By Regulation, May Take 45 Days To Review Application To Determine If Complete. If Filed, FDA Begins Substantive Review. E. FDA Refusal To File PMA. 1. FDA May By Letter Cite Deficiencies In PMA And Refuse To Accept For Filing. 2. Sponsor May Contest Deficiencies. 3. Sponsor May, Within 10 Working Days, Request Informal Conference With Office Of Device Evaluation (ODE). 4. ODE Will Hold An Informal Conference Within 10 Working Days Of Its Receipt Of Sponsor's Request. 5. ODE Will Advise Sponsor Within 5 Working Days After Conference If PMA To Be Filed. 6. Sponsor May Request Reconsideration By Director Of CDRH. 7. Guidance Document -- Center For Devices And Radiological Health s Premarket Approval Application (PMA) Refuse To File Policy (6/30/93). F. Scope Of Review Limited To Conditions Of Use Submitted In Proposed Labeling (FDCA 515(d)(1)(A)). G. Review By Advisory Committee (FDCA 515(c)(2)). 1. FDA May Refer PMA To Advisory Committee On Its Own Initiative Or Upon The Request Of Applicant. 2. Meeting On PMA Is Public Except for Discussion of Confidential Information. 3. Panel Must Provide Report And Recommendation On PMA To FDA. H. Planning For And Meeting With Panel. 1 Obtain From Executive Secretary Copies Of All Material Submitted To Panel -- Pursuant To 21 C.F.R Obtain Information Regarding Panel Consultants. 3 Attend Public Meeting Or Obtain Transcript From Prior Panel Meetings. 4 FDAMA Reforms (FDCA 513(b)(6)(A)). a. Same Access To Data And Information As FDA; 4
5 b. Same Opportunity To Submit Additional Information As FDA; c. Same Opportunity To Participate As FDA; d. FDA Must Notify Applicant In Writing After Making Decision, Detailed Reasons For Variation From Panel Recommendations. e. Guidance on Amended Procedures for Advisory Panel Meetings (Jan. 26, 1999). I. Day-100 Meeting (FDCA 515(d)(3)). 1. Meeting To Discuss Status Of Review. 2. Must Be Requested Either When The PMA Is Filed Or No Later Than 70 Days After Filing. See Guidance on PMA Interative Procedures for Day- 100 Meetings and Subsequent Deficiencies for Use by CDRH and Industry (Feb. 19, 1998). J. Approval/Denial Of PMA. 1. Approval Order (21 C.F.R (d)). 2. Approvable Letter (21 C.F.R (e)). 3. Not Approvable Letter (21 C.F.R (f)). 4. Denial Order (21 C.F.R ) With A Finding Of: K. Modular PMAs. a. Lack Of Reasonable Assurance Of Safety Or Effectiveness. b. Lack Of GMP In Manufacturing. c. Labeling False And/Or Misleading. d. Failure To Conform To Performance Standard. e. Sponsor May Appeal Denial Order To Special Panel. f. Special Panel Decision May Be Appealed To Court. 1. Review Of The PMA In Pieces Or Modules. 2. Allows For Closure Of One Or More Modules Before PMA Is Submitted (e.g., manufacturing information). 3. PMA Shell Outline of Sections. 5
6 4. Guidance for Industry: Guidances for the Medical Device Industry on PMA Shell Development and Modular Review (Nov. 6, 1998) [Exhibit 3]. L. Use And Availability Of PMA Data. 1. FDAMA Repealed "Four-Of-A-Kind" Rule For Release of PMA Data By Which Certain Clinical And Preclinical Test Data Compiled To Prove Safety And Effectiveness Would Become Available For Use By The Agency One Year After The Application For The Fourth Device "Of A Kind" Is Approved. This Rule Is Replaced With A Similar Provision By Which The Data Is Available Six Years After The Approval Of The Application That Is The Source Of The Data. Note: method of manufacture and composition of material remains confidential. Note: FDA has never declared that four devices "of a kind have been approved. 2. PMA Guidances -- FDA Has Published Guidances On Various Devices And Testing Protocols For Devices. M. Dispute Resolution Process. See Guidance: Resolving Scientific Disputes concerning the Regulation of Medical Devices, A Guide to Use of The Medical Devices Dispute Resolution Panel, (7/2/01) [Exhibit 4]. II. MAKING CHANGES TO PMA APPROVED DEVICES PMA SUPPLEMENTS A. Device Changes Affecting Safety Or Effectiveness Require Approval Of A PMA Supplement (21 C.F.R ). 1. Examples Of Changes That Require A Supplement If Affecting Safety Or Effectiveness: a. New Indications For Use; b. Labeling Changes; c. Change in Manufacturing, Processing, Or Packaging Facility; d. Changes In Sterilization Procedures; e. Changes In Packaging; f. Changes In Specifications, Circuits, Components, Ingredients, Principle Of Operation, Or Physical Layout; or 6
7 g. Extension Of Expiration Date Based On Data From An Unapproved Stability Protocol. 2. PMA Holder s Obligation To Determine If A Supplement Is Required. Draft Guidance: Guidance for Industry: Modifications To Devices Subject to Premarket Approval The PMA Supplement Decision Making Process (Aug. 6, 1998) [Exhibit 5] Day Review Period. B. Special PMA Supplement Changes Being Effected Used For Changes That Enhance Safety. 21 C.F.R (d) 1. Do Not Have To Wait For FDA Approval, But Must Wait For Acknowledgment. 2. May Be Used For The Following Changes: a. Strengthening Of Warnings, Contraindications, Or Precautions; b. Adding Or Strengthening An Instruction Intended To Enhance The Safe Use Of The Device; c. Deletion Of Misleading, False, Or Unsupported Indications; d. Quality Control Changes That Provide Additional Assurance Of Purity, Identity, Strength, Or Reliability. C. 30-Day Notice Used For Changes In Manufacturing That Affect Safety And Effectiveness. FDCA 515(d)(6); 21 C.F.R (f). 1. Notify FDA Of A Modification To The Manufacturing Procedures Made In Accordance With QSRs. 2. May Implement Change 30 Days After FDA Receives The Notice Unless FDA Notifies The Manufacturer That The Notice Is Inadequate. 3. If A PMA Supplement Is Required Time Under Review As A 30-Day Notice Is Subtracted From The 135 Day Review Period. D. Changes That Do Not Affect Safety Or Effectiveness Can Be Documented In File Or, If Required By FDA, Reported In Annual (or Periodic) Reports. III. PRODUCT DEVELOPMENT PROTOCOLS (PDP) A. Alternative To Submission Of PMA. 7
8 B. FDA And Applicant Reach Pre-Application Agreement As To Data Requirements For Approval Of Device. Completion Of Protocol Results In Approval Of Device. C. FDA Has Not Issued Regulations. D. FDA Draft Guidance, Contents Of A Product Development Protocol (5/14/98) (Full Text Available At [ E. Usually Works Best for Devices Already Well Understood By FDA. IV. HUMANITARIAN DEVICE EXEMPTION (HDE) (FDCA 520(m); 21 C.F.R. Part 814, Subpart H) A. Allows Marketing Of A Humanitarian Use Device (HUD) Without Reasonable Assurance Of Effectiveness. B. Limited To Devices Intended To Benefit Patients In The Treatment Or Diagnosis Of Diseases Or Conditions That Affect Or Are Manifested In Fewer Than 4,000 Individuals In The U.S. Per Year. C. Amount Charged For The Device Cannot Exceed The Costs Of the Research, Development, Fabrication, And Distribution. D. After Approval, Must Periodically Provide Detailed Information On Cost, Safety, And Continued Justification For HUD Status. E. Must Be Used Only Under The Review Of An Institutional Review Board ( IRB ). 8
PMAs, 510(k)s, and Advanced IDE Topics
PMAs, 510(k)s, and Advanced IDE Topics Kenneth J. Cavanaugh Jr., Ph.D. Scientific Reviewer Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health kenneth.cavanaugh@fda.hhs.gov
More informationGuidance on IDE Policies and Procedures
Guidance on IDE Policies and Procedures This document is intended to provide guidance. It represents the Agency s current thinking on the above. It does not create or confer any rights for or on any person
More informationIVD Regulation Overview. Requirements to Assure Quality & Effectiveness
IVD Regulation Overview Requirements to Assure Quality & Effectiveness CLIAC Jan. 2002 Statutory and Regulatory Requirements Statute: Food, Drug, and Cosmetic Act Food and Drugs Act of 1906 Food and Drug
More informationGuidance for Industry and Food and Drug Administration Staff
Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff Guidance for Industry and Food and Drug Administration Staff Document
More informationInformation Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Frequently Asked Questions About Medical Devices Additional copies are available from: Office of Good Clinical Practice Office
More informationGuidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationGuidance for Industry
Guidance for Industry FDA Export Certificates Submit comments and suggestions regarding this document at anytime to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
More informationGuidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program DRAFT GUIDANCE This guidance document is being distributed for comment purposes
More informationInformation Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors FDA Institutional Review Board Inspections Additional copies are available from: Office of Good Clinical Practice Office of Special
More informationJUL 2 2008. Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA 95054-2807
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service JUL 2 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular
More informationGuidance for Industry Classifying Resubmissions in Response to Action Letters
Guidance for Industry Classifying Resubmissions in Response to Action Letters U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More informationGuidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols
Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols For questions on the content of this document contact Leonard Wilson, CBER at 301-827-0373 or Susan Johnson, CDER
More informationClinical evaluation Latest development in expectations EU and USA
Clinical evaluation Latest development in expectations EU and USA Medical Devices: staying ahead of regulatory developments Gert Bos BSI Israel 22 April - Herzliya Copyright 2012 BSI. All rights reserved.
More informationMedical Billing and Agency Formal Disputes
Guidance for Industry Formal Dispute Resolution: Appeals Above the Division Level Additional copies of this Guidance are available from: Office of Training and Communications Division of Communications
More information) 1 1 > 1 FDA Docket No. 02H-0443 1 ) ) ) ) 1 1 ) 1 )
UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES In the matter of LAHAYE CENTER FOR ADVANCED EYE CARE OF LAFAYETTE, D/B/A LAHAYE TOTAL EYE CARE,
More informationGuidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA
Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More information21st Century Cures Act: Key Provisions Related to Medical Devices
21st Century Cures Act: Key Provisions Related to Medical Devices July 30, 2015 Food & Drug The 21st Century Cures Act ( the Act or HR 6 ) was passed by the House of Representatives on July 10, 2015, by
More informationORACLE CONSULTING GROUP
ORACLE CONSULTING GROUP An Official United States Agent Firm for Foreign Establishments CONSULTING MEMORANDUM: DEALING WITH A MEDICAL DEVICE IN THE U.S. 5398 Golder Ranch Rd., Ste. 1 Tucson, Arizona 85739
More informationMedical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices
Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE This guidance document
More informationCombination Products Regulation in the United States
Combination Products Regulation in the United States Presenter: Scott Sardeson RAC US/EU 3M Health Care St. Paul, MN USA 1 Presentation Outline Combination products Definitions and Regulations Jurisdiction
More informationTotal Product Lifecycle Solutions from NSF Health Sciences Medical Devices
Total Product Lifecycle Solutions from NSF Health Sciences Medical Devices Experts in medical device quality systems, compliance, regulatory affairs, auditing and training www.nsf.org The Right People.
More informationPage 191 TITLE 21 FOOD AND DRUGS 355 1
Page 191 TITLE 21 FOOD AND DRUGS 355 1 APPEALS TAKEN PRIOR TO OCTOBER 10, 1962 Section 104(d)(3) of Pub. L. 87 781 made amendments to subsec. (h) of this section inapplicable to any appeal taken prior
More informationGuidance for Industry Time and Extent Applications for Nonprescription Drug Products
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
More informationDavid M. Stern, M.D. JAN 2 9 7007 Dean, University of Cincinnati College of Medicine 231 Albert Sabin Way Cincinnati, OH 45267
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Serv ice Food and Drug Administration 9200 Corporate Boulevard Rockville, Ma ry land 20850 WARNING LETTER VIA FEDERAL EXPRESS David M. Stern, M.D. JAN
More informationRefuse to Accept Policy for 510(k)s. Guidance for Industry and Food and Drug Administration Staff
Refuse to Accept Policy for 510(k)s Guidance for Industry and Food and Drug Administration Staff Document issued on: December 31, 2012 This document supersedes Center for Devices and Radiological Health
More informationGood Clinical Practice 101: An Introduction
Good Clinical Practice 101: An Introduction Presented by: Lester Jao Lacorte, MD Medical Officer Commissioner s Fellow Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Jabones Pardo S.A.
More informationFebruary 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
More informationAugust 18, 2015. Re: Section 1201 Rulemaking Proposed Exemption for Medical Devices
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 August 18, 2015 Ms. Jacqueline C. Charlesworth General Counsel
More informationGuidance for Industry Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act
Guidance for Industry Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act DRAFT GUIDANCE This guidance document is being distributed for comment purposes
More informationContains Nonbinding Recommendations
FY 2016 Medical Device User Fee Small Business Qualification and Certification Guidance for Industry, Food and Drug Administration Staff and Foreign Governments Document issued on August 3, 2015. As of
More informationUW MEDICINE IDE/HDE DEVICE COVERAGE AND BILLING MAY, 2013
UW MEDICINE IDE/HDE DEVICE COVERAGE AND BILLING MAY, 2013 DEFINITIONS Investigational Device Exemption (IDE)- An approved IDE means that an IRB (and FDA for significant risk devices) has approved the sponsor
More informationTITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER H--MEDICAL DEVICES
[Code of Federal Regulations] [Title 21, Volume 8] [Revised as of April 1, 2010] [CITE: 21CFR807] TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationGuidance for Industry
Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products For questions on the content of the guidance,
More informationPREP Course #27: Medical Device Clinical Trial Management
PREP Course #27: Medical Device Clinical Trial Management Presented by: Evelyn Huang Jeffrey Revello Office of Research Compliance North Shore-LIJ Health System CME Disclosure Statement The North Shore
More informationUNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM. DoD/DON-funded Research
UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM DoD/DON-funded Research Policy In 2006, the Department of the Navy (DON) enhanced its human subject protection requirements, including
More informationGuidance for Industry
Guidance for Industry Promoting Medical Products in a Changing Healthcare Environment; I. Medical Product Promotion by Healthcare Organizations or Pharmacy Benefits Management Companies (PBMs) DRAFT GUIDANCE
More informationHow To Get A Plant Variety Right In Estonia
PLANT VARIETY RIGHTS ACT Passed 25 March 1998 (RT 11998, 36/37, 553), entered into force I July 1998, amended by the following Act: 19.01.2000 entered into force 0 1.03.2000 - RT 12000, 10, 56. CHAPTER
More informationMarketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice
Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Kurt R. Karst Hyman, Phelps & McNamara, P.C. 700 Thirteenth Street, N.W., Suite 1200 Washington, D.C.
More informationGuidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions U.S. Department of Health and Human Services Food and Drug Administration
More informationChapter 8 WHAT THE STATUTE AND REGULATIONS SAY. Combination Products. Key Points
Chapter 8 Combination Products Suzanne O Shea, Baker & Daniels, LLP, Indianapolis, IN Key Points A combination product comprises two or more different types of regulated components. It can be a drug/device,
More informationALTERNATIVE TRADING SYSTEM RULES
ALTERNATIVE TRADING SYSTEM RULES (text according to legal condition at 20 June 2012) 1 NOTE: Only the Polish version of this document is legally binding. This translation is provided for information only.
More informationB I L L. No. 183 An Act to amend The Saskatchewan Employment Act and The Saskatchewan Employment Amendment Act, 2014
B I L L No. 183 An Act to amend The Saskatchewan Employment Act and The Saskatchewan Employment Amendment Act, 2014 (Assented to ) HER MAJESTY, by and with the advice and consent of the Legislative Assembly
More informationFDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle
FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle Kurt R. Karst Associate Hyman, Phelps & McNamara, P.C. 700 Thirteenth
More informationContains Nonbinding Recommendations
Guidance for Industry and FDA Staff Laser Products Conformance with IEC 60825-1 and IEC 60601-2-22; Guidance for Industry and FDA Staff (Laser Notice No. 50) Document issued on June 24, 2007 This document
More informationGuidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
More informationThe draft of this document issued on December 27, 2011.
The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)] Guidance for Industry and Food and Drug Administration Staff Document issued on: July 28, 2014 The draft of this
More informationG. Recalls. http://www.fda.gov/safety/recalls/industryguidance/ucm129259.htm.
G. Recalls 1. Background When an FDA-regulated product is defective, potentially harmful, or mislabeled, recalling that product removing it from the market or correcting the problem is often the most effective
More informationWhat is a medical device? Medical Devices: Roadmap to Market. Kathryn Klaus, Esq.
Medical Devices: Roadmap to Market Kathryn Klaus, Esq. The last installment of Regulatory 360 discussed the FDA organization in general where it came from and a broad overview of how it operates, as well
More informationTHE FREEDOM OF INFORMATION ACT A User s Guide
THE FREEDOM OF INFORMATION ACT A User s Guide By The Freedom of Information Clearinghouse A Project of Ralph Nader (Revised 11/05) The Freedom of Information Act ( FOIA ) was enacted by Congress in 1966
More informationGuidance for Industry
Guidance for Industry Major, Minor, and Telephone Amendments to Abbreviated New Drug Applications Comments and suggestions regarding this document should be submitted within 90 days of publication in the
More informationState and Territory Coastal Management Program Managers
MEMORANDUM FOR: FROM: SUBJECT: State and Territory Coastal Management Program Managers Jeffrey R. Benoit Director Final Program Change Guidance Attached is the Office of Ocean and Coastal Resource Management
More informationDISCLOSURE OF ACCREDITING DOCUMENTS AND ACTIONS OF THE SOUTHERN ASSOCIATION OF COLLEGES AND SCHOOLS COMMISSION ON COLLEGES (SACSCOC)
Southern Association of Colleges and Schools Commission on Colleges 1866 Southern Lane Decatur, Georgia 30033-4097 DISCLOSURE OF ACCREDITING DOCUMENTS AND ACTIONS OF THE SOUTHERN ASSOCIATION OF COLLEGES
More informationQ(K SVJM~jPagelIof 3
K13 0460 Q(K SVJM~jPagelIof 3 JUL 1 12013 This 51 0(k) Summary is being submitted in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The content contained in this 510(k)
More informationUnique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff
Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff Document issued on August 20, 2014. On November 5, 2014 this document was
More informationGuidance for Industry and FDA Staff Tonometers - Premarket Notification [510(k)] Submissions
Guidance for Industry and FDA Staff Tonometers - Premarket Notification [510(k)] Submissions Document issued on: March 27, 2006 For questions regarding this document, contact Everette Beers, Ph.D. at 240-276-4200
More informationClinical trials for medical devices: FDA and the IDE process
Clinical trials for medical devices: FDA and the IDE process Owen Faris, Ph.D. Deputy Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health,
More informationRisk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry The portion of this guidance document setting forth the submission procedures for risk evaluation and mitigation
More informationTriangle Compounding 11/2/15
Triangle Compounding 11/2/15 Department of Health and Human Services Public Health Service Food and Drug Administration Atlanta District 60 Eighth Street NE Atlanta, GA 30309 November 2, 2015 VIA UNITED
More informationOctober 28, 2013 MORTGAGEE LETTER 2013-39. All Approved Mortgagees, Single Family Servicing Managers. Methods of Communication with Borrowers
U.S. DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT WASHINGTON, DC 20410-8000 ASSISTANT SECRETARY FOR HOUSING- FEDERAL HOUSING COMMISSIONER October 28, 2013 MORTGAGEE LETTER 2013-39 To All Approved Mortgagees,
More informationJosephine County, Oregon Board of Commissioners: Jim Riddle, Jim Raffenburg, Dwight Ellis
Josephine County, Oregon Board of Commissioners: Jim Riddle, Jim Raffenburg, Dwight Ellis APPEAL APPLICATION Hearings Officer or Planning Commission Decision (Fee: $1250) PLANNING OFFICE Michael Snider,
More informationJN2620. 4. 510(k) Summary. 4.1.4 Device Identification: 4.1.6 Device Description:
4. 510(k) Summary 4.1.1 Sponsor: Beau Rx Solutions, LLC 1440 South Ocean Blvd #5C JN2620 Lauderdale by the Sea, Fl 33062 4.1.2 Contact: Thomas L McGraw, President Phone: 1-954-817-6155 Fax 1-954-782-0018
More informationNDA 021879 NDA APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021879 NDA APPROVAL Avanir Pharmaceuticals Attention: Randall Kaye, M.D. Vice President, Clinical and Medical
More informationHow to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters
environmental failure analysis & prevention health technology development How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters Kevin L. Ong, Ph.D., P.E. Managing
More informationSUPPORTING STATEMENT FOR Hearing Aid Devices, Professional and Patient Labeling and Conditions for Sale 21 CFR 801.420 and 801.421 OMB No.
A. JUSTIFICATION SUPPORTING STATEMENT FOR Hearing Aid Devices, Professional and Patient Labeling and Conditions for Sale 21 CFR 801.420 and 801.421 OMB No. 0910-0171 1. Circumstances Making the Collection
More informationCustom Device Exemption. Draft Guidance for Industry and Food and Drug Administration Staff
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Custom Device Exemption Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE This guidance
More informationSection 19(b)(2) * Section 19(b)(3)(A) * Section 19(b)(3)(B) *
OMB APPROVAL Required fields are shown with yellow backgrounds and asterisks. OMB Number: 3235-0045 Estimated average burden hours per response...38 Page 1 of * 30 SECURITIES AND EXCHANGE COMMISSION WASHINGTON,
More informationGuidance for Industry Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions
Guidance for Industry Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions U.S. Department of Health and Human Services Food and Drug Administration Center for
More informationAugust 21, 2015. TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 Mr. Iain Alligan Technical
More informationDepartment of Defense INSTRUCTION
Department of Defense INSTRUCTION NUMBER 6200.02 February 27, 2008 SUBJECT: Application of Food and Drug Administration (FDA) Rules to Department of Defense Force Health Protection Programs USD(P&R) References:
More informationRoles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
More informationLicence Appeal Tribunal
Licence Appeal Tribunal Safety, Licensing Appeals and Standards Tribunals Ontario (SLASTO) Rules of Practice Revised: May 1, 2014 Disponible en français TABLE OF CONTENTS Contents Page 1. DEFINITIONS...
More informationDICOM Grid, Inc. January 25, 2016. Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 DICOM Grid, Inc. Senior
More informationPROPOSED AMENDMENTS TO HOUSE BILL 2240
HB 0- (LC ) // (LHF/ps) PROPOSED AMENDMENTS TO HOUSE BILL 0 1 1 0 1 On page 1 of the printed bill, line, after ORS delete the rest of the line and delete lines through and insert.,.00,.0,.0,.01,.01,.1,.,.,.,.,
More informationKoqo8 go. ER35 ERO-SCAN Pro Hearing Test System. 61 Martin Lane Elk Grove Village, IL 60007. Manager of Instrumentation Products
Koqo8 go Traditional 510(k) Premarket Notification ER35 ERO-SCAN Pro Hearing Test System Page 6 3.0 510(K) SUMMARY Submission Date: March 30, 2007 Submitter Information: Company Name: Company Address:
More informationGuidance for Industry
Guidance for Industry Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed
More informationDatrix, Inc NOV - 1 2005. Appendix G. 510(k) Summary of Safety and Effectiveness for Datrix, Inc CardioServer ECG Management System
Appendix G NOV - 1 2005 510(k) Summary of Safety and Effectiveness for CardioServer ECG Management System 1. DATE SUMMARY PREPARED: 9-26-2005 2. SUBMITTER'S NAME AND ADDRESS: Linda Gluckman 340 State Place
More informationGuidance for IRBs, Clinical Investigators, and Sponsors. Considerations When Transferring Clinical Investigation Oversight to Another IRB
Guidance for IRBs, Clinical Investigators, and Sponsors Considerations When Transferring Clinical Investigation Oversight to Another IRB U.S. Department of Health and Human Services Food and Drug Administration
More informationATLANTIS Anterior Cervical Plate System ATLANTIS Translational Plate. 510(k) Summary. February 2007
rk,1 10{2 ATLANTIS Anterior Cervical Plate System ATLANTIS Translational Plate 510(k) Summary FEB 2 3 2[007 February 2007 I. Company: Medtronic Sofamor Danek USA 1800 Pyramid Place Memphis, Tennessee 38132
More informationCHAPTER 14 DIRECTOR, DIVISION OF HEALTH SERVICE REGULATION SUBCHAPTER 14A RULEMAKING SECTION.0100 - RULEMAKING
CHAPTER 14 DIRECTOR, DIVISION OF HEALTH SERVICE REGULATION SUBCHAPTER 14A RULEMAKING SECTION.0100 - RULEMAKING 10A NCAC 14A.0101 PETITIONS (a) Any person wishing to submit a petition requesting the adoption,
More informationPDUFA REAUTHORIZATION PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017
PDUFA REAUTHORIZATION PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017 I. REVIEW PERFORMANCE GOALS A. NDA/BLA Submissions and Resubmissions B. Original Efficacy Supplements C. Resubmitted
More informationThe MDUFMA User Fee Program in 2005: A Critical Year
The MDUFMA User Fee Program in 2005: A Critical Year Jennifer A. Henderson, J.D., M.P.H. 1 Brooke C. Alexander, B.A. 2 Anne P. Lewis, B.A. 3 John J. Smith, M.D., J.D. 4 1 Acting Director, Regulatory Affairs
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Internet/Social Media Platforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document
More informationApplication Submitted on Received on Supplement type NDA 021875/S-005 July 24, 2008 July 25, 2008 Changes Being Effected
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021875/S-005, S-008, S-015 SUPPLEMENT APPROVAL Cephalon Inc. Attention: Paul Kirsch Senior Director and Group
More informationIntroduction to Compliance with FDA Labeling and Advertising Requirements
Introduction to Compliance with FDA Labeling and Advertising Requirements Second Annual Pharmaceutical Industry Regulatory and Compliance Summit Dick Kenny FDA History Basic function of government Oldest
More information510(k) SUMMARY MANI Needle and Suture Pack MANI, Inc.
510(k) SUMMARY MANI Needle and Suture Pack MANI, Inc. This 51 0(k) summary of safety and effectiveness for the MANI Needle and Suture Pack (Poly(ethylene terephthalate)) is submitted in accordance with
More information2:00-mc-00005-DPH Doc # 1027 Filed 05/22/15 Pg 1 of 38 Pg ID 17325
2:00-mc-00005-DPH Doc # 1027 Filed 05/22/15 Pg 1 of 38 Pg ID 17325 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION IN RE: CASE NO. 00-CV-00005-DT (Settlement Facility Matters)
More informationSTATUS [ ] For office use only
CITY OF CHICAGO DEPARTMENT OF REVENUE GROUND TRANSPORTATION TAX - 7595US FOR USE BY APPROVED APPLICANTS OF UNDERSERVED AREAS CREDIT PROGRAM ONLY STATUS [ ] For office use only ACCOUNT NUMBER DUE DATE CHECK
More informationAn Agricultural Law Research Note
A research project from The National Center for Agricultural Law Research and Information of the University of Arkansas NatAgLaw@uark.edu (479) 575-7646 www.nationalaglawcenter.org An Agricultural Law
More informationFormal FDA Meeting Request: Guidance and Template
Formal FDA Meeting Request: Guidance and Template ICTR Navigators July 23, 2011 Version 2.0 Page 1 of 20 1.0 Table of Contents Section Page 1.0 Table of Contents 2 2.0 Abbreviations 2 3.0 FDA Regulations
More informationComparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP
Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP Document issued on: June 2004 U.S. Department of Health and Human Services Food and Drug Administration
More informationThe Food and Drug Administration's Policy on Declaring Small Amounts of Nutrients and
This document is scheduled to be published in the Federal Register on 07/01/2016 and available online at http://federalregister.gov/a/2016-15477, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationAgreements and Memoranda of Understanding Between the Food and Drug Administration and
This document is scheduled to be published in the Federal Register on 03/23/2012 and available online at http://federalregister.gov/a/2012-06969, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationQuality System: Design Control Procedure - Appendix
Quality System: Design Control Procedure - Appendix Page 1 of 10 Quality System: Design Control Procedure - Appendix CORP Medical Products Various details have been removed, indicated by [ ] 1. Overview
More informationMay 7, 2015. Tactile Systems Technology Inc Daniel Chase V.P. Engineering & Operations 1331 Tyler St NE Minneapolis, Minnesota 55413
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 May 7, 2015 Tactile Systems Technology Inc Daniel
More informationUNITED STATES OF AMERICA FEDERAL TRADE COMMISSION
UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION ) In the Matter of ) FILE NO. ) ACRAnet, INC., ) AGREEMENT CONTAINING a corporation. ) CONSENT ORDER ) ) The Federal Trade Commission ( Commission ) has
More informationRULE. Office of the Governor Real Estate Appraisers Board. Appraisal Management Companies (LAC 46:LXVII.Chapters 301-309)
RULE Office of the Governor Real Estate Appraisers Board Appraisal Management Companies (LAC 46:LXVII.Chapters 301-309) Under the authority of the newly enacted Appraisal Management Company Licensing and
More informationJanuary 12, 2016. Dear Amy Yang:
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 January 12, 2016 Amy
More informationMassachusetts Statewide Records Retention Schedule 02-11 August 2014 Supplement www.sec.state.ma.us/arc/arcrmu/rmuidx.htm
Massa achusetts Statewide Records Retention Schedule 02-11 August 2014 Supplement www.sec.state.ma.us/arc/arcrmu/rmuidx.htm Summary of Contents About This Supplement... 7 Revisions to the Current Edition...
More information